Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Biological nitric oxide signalling: chemistry and terminology.
Heinrich TA, da Silva RS, Miranda KM, Switzer CH, Wink DA, Fukuto JM. Heinrich TA, et al. Br J Pharmacol. 2013 Aug;169(7):1417-29. doi: 10.1111/bph.12217. Br J Pharmacol. 2013. PMID: 23617570 Free PMC article. Review.
Biological nitrogen oxide signalling and stress is an area of extreme clinical, pharmacological, toxicological, biochemical and chemical research interest. The utility of nitric oxide and derived species as signalling agents is due to the
Biological nitrogen oxide signalling and stress is an area of extreme clinical, pharmacological, toxicological, biochem
Coordination of non-innocent nitrogen oxide ligands: terminology.
Miranda KM. Miranda KM. J Biol Inorg Chem. 2019 May;24(3):315-316. doi: 10.1007/s00775-019-01659-0. Epub 2019 Apr 29. J Biol Inorg Chem. 2019. PMID: 31037467
This practice has expanded with the discovery that nitrogen oxides serve as biological signaling agents. This commentary addresses the recent introduction of a new term for metal nitrosyl complexes upon reduction and suggests a community-based approach to changes in …
This practice has expanded with the discovery that nitrogen oxides serve as biological signaling agents. This commentary addre …
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Hong DS, et al. Cancer. 2014 Jul 15;120(14):2164-73. doi: 10.1002/cncr.28701. Epub 2014 Apr 17. Cancer. 2014. PMID: 24752867 Free article. Clinical Trial.
BACKGROUND: The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor). ...Cediranib was give …
BACKGROUND: The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothe …